Catheter Ablation vs Drug Therapy for Atrial Fibrillation: Insights from the CABANA Trial by Nonmodifiable Risk Profiles

Highlight

• Catheter ablation significantly reduces cardiovascular events in AF patients with fewer than three nonmodifiable risk factors.
• Patients with three or more nonmodifiable risk factors do not exhibit significant cardiovascular benefit from ablation compared to drug therapy.
• Across all risk groups, ablation lowers AF recurrence and improves quality of life related to symptom frequency.
• Mortality benefit remains uncertain, emphasizing the need for personalized AF management approaches.

Study Background and Disease Burden